OBJECTIVE： To compare effectiveness and economical efficiency of valsartan/amlodipine compound preparation versus angiotensin receptor blockers （ARB）+calcium channel blockers （CCB） in the treatment of hypertension. METHODS： Retrieved from English databases as Medline， PubMed， Cochrane Library， and Chinese databases as CNKI， VIP， Wanfang database， retrieval range were “Title/Abstract”； retrieval terms were “Valsartan/Amlodipine” and “Hypertension”； retrieval time limit was from database establishment to May 2018. By Markov model， based on drug price and medical cost in 2017， the effectiveness and economical efficiency of valsartan/amlodipine compound preparation group in the included literatures were compared with that of ARB+CCB group. RESULTS： From the perspective of medical and health system， treatment cost per capita of nonfatal myocardial infarction and nonfatal stroke in Markov model of valsartan/amlodipine compound preparation group were lower than ARB+CCB group. Compared with ARB+CCB group， incremental utility of valsartan/amlodipine compound preparation group was the incremental cost was 2 916.63 yuan for quality adjusted life year （QALY） increasing each 0.067 8 units. The incremental cost-effectiveness ratio was 42 988.44 yuan/QALY. CONCLUSIONS： Compared with ARB+CCB， valsartan/amlodipine compound preparation for hypertension can significantly reduce the occurrence of adverse events such as nonfatal myocardial infarction and nonfatal stroke， and save the medical expenses for the patients. It is more economical.